Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

549
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
549
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

3.3K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
3.3K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

2.8K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.8K
Asthma-I: Introduction01:29

Asthma-I: Introduction

2.8K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.8K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

415
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
415

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Airway Mucus Plugs in Asthma and COPD: Pathobiology, Imaging, and Implications for Clinical Trials.

American journal of respiratory and critical care medicine·2026
Same author

Beta<sub>2</sub>-agonist and anti-inflammatory combination therapy for asthma rescue: a paradigm shift in asthma care.

Frontiers in medicine·2026
Same author

Real-world effects of asthma biologics on blood eosinophil levels: data from the CHRONICLE study.

The Journal of asthma : official journal of the Association for the Care of Asthma·2026
Same author

Disease Burden of Asthma Patients Utilizing Short-Acting Beta-2 Agonist-Only Inhalers as Rescue in the United States.

Journal of asthma and allergy·2026
Same author

Fish diversity and community turnover across protection zones in multiuse marine protected areas.

Conservation biology : the journal of the Society for Conservation Biology·2026
Same author

Clinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.

Gastroenterology·2026
Same journal

Does taking BP medicine at night (vs morning) result in fewer cardiovascular events?

The Journal of family practice·2023
Same journal

Preventing RSV in children and adults: A vaccine update.

The Journal of family practice·2023
Same journal

Essential oils: How safe? How effective?

The Journal of family practice·2023
Same journal

51-year-old woman • History of Graves disease • General fatigue, palpitations, and hand tremors • Dx?

The Journal of family practice·2023
Same journal

Renewing the dream.

The Journal of family practice·2023
Same journal

55-year-old woman • Myalgias and progressive symmetrical proximal weakness • History of unilateral renal agenesis, type 2 diabetes, and hyperlipidemia • Dx?

The Journal of family practice·2023
See all related articles

Related Experiment Video

Updated: Sep 1, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.0K

A Paradigm Shift for Asthma Care.

Njira Lugogo1, Neil Skolnik2, Yihui Jiang3

  • 1Njira Lugogo, MD, MS, Associate Professor of Internal Medicine, University of Michigan; Director, Michigan Medicine Asthma Program, Ann Arbor, Michigan.

The Journal of Family Practice
|August 12, 2022
PubMed
Summary
This summary is machine-generated.

Short-acting beta2-agonist (SABA) rescue therapy alone increases asthma exacerbation risk. Combining a fast-acting bronchodilator with inhaled corticosteroids (ICS) offers better protection against asthma attacks.

More Related Videos

Asthma Detection Research Based on Voice Signal Processing and Machine Learning
04:04

Asthma Detection Research Based on Voice Signal Processing and Machine Learning

Published on: July 22, 2025

364
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.8K

Related Experiment Videos

Last Updated: Sep 1, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.0K
Asthma Detection Research Based on Voice Signal Processing and Machine Learning
04:04

Asthma Detection Research Based on Voice Signal Processing and Machine Learning

Published on: July 22, 2025

364
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.8K

Area of Science:

  • Pulmonology
  • Allergy and Immunology
  • Pharmacology

Background:

  • Asthma management continues to evolve, yet remains a significant health concern.
  • Patients with mild to moderate asthma face risks of severe exacerbations, even with intermittent symptoms.
  • Short-acting beta2-agonist (SABA) monotherapy for rescue is linked to increased exacerbation frequency.

Purpose of the Study:

  • To evaluate the efficacy of fast-acting bronchodilator plus inhaled corticosteroids (ICS) as a rescue therapy for asthma.
  • To explore the potential of combination inhalers in mitigating asthma exacerbation risk.
  • To address the unmet need for a fixed-dose, fast-acting bronchodilator and ICS combination for as-needed use.

Main Methods:

  • Review of current evidence on asthma rescue therapies.
  • Analysis of risk factors associated with SABA-only therapy.
  • Exploration of treatment paradigms involving combination inhalers.

Main Results:

  • SABA-only rescue therapy is associated with a higher risk of asthma exacerbations.
  • Fast-acting bronchodilator plus ICS demonstrates greater efficacy in reducing exacerbations compared to SABA alone.
  • A critical window exists pre-exacerbation where combination therapy may prevent severe events.

Conclusions:

  • Combining a fast-acting bronchodilator with ICS, particularly in a combination inhaler, may be more effective for asthma rescue than SABA alone.
  • This approach offers a potential strategy to mitigate exacerbation risk in patients with mild to moderate asthma.
  • Current lack of an approved fixed-dose fast-acting bronchodilator/ICS combination for as-needed use in the US represents a treatment gap.